Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine-induced weight gain

Young Min Park, Jung Eun Choi, Seung Gul Kang, Seung-Hoi Koo, Leen Kim, Dongho Geum, Heon-Jeong Lee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background Olanzapine is an atypical antipsychotic known to cause considerable weight gain. The cannabinoid type 1 receptor has been reported to be involved in energy balance control, appetite stimulation, and increases in body weight. Methods In the present study, we investigated three polymorphisms (rs1049353, rs806368, and rs4707436) in the cannabinoid type 1 receptor gene (CNR1) and weight gain in Korean patients with schizophrenia receiving olanzapine treatment. Weight and height were measured prior to starting olanzapine and again after long-term treatment in 78 patients with schizophrenia. CNR1 polymorphisms were genotyped using PCR-RFLP methods. Results The three CNR1 polymorphisms were not associated with body weight changes from baseline to the endpoint after olanzapine treatment (p > 0.05). There were also no significant differences in genotype, allele, or haplotype frequencies between the high weight gain (at least 7%) and low weight gain (less than 7%) groups. Conclusion Within the limitations imposed by the smallness of the clinical sample, our findings suggest that CNR1 polymorphisms are not associated with olanzapine-induced weight gain.

Original languageEnglish
Pages (from-to)332-337
Number of pages6
JournalHuman Psychopharmacology
Volume26
Issue number4-5
DOIs
Publication statusPublished - 2011 Jun 1

Fingerprint

olanzapine
Cannabinoid Receptors
Weight Gain
Genes
Schizophrenia
Body Weight Changes
Appetite
Restriction Fragment Length Polymorphisms
Haplotypes
Antipsychotic Agents
Therapeutics
Alleles
Genotype
Body Weight
Weights and Measures
Polymerase Chain Reaction

Keywords

  • cannabinoid receptor
  • olanzapine
  • polymorphism
  • schizophrenia
  • weight gain

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Pharmacology (medical)

Cite this

Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine-induced weight gain. / Park, Young Min; Choi, Jung Eun; Kang, Seung Gul; Koo, Seung-Hoi; Kim, Leen; Geum, Dongho; Lee, Heon-Jeong.

In: Human Psychopharmacology, Vol. 26, No. 4-5, 01.06.2011, p. 332-337.

Research output: Contribution to journalArticle

@article{cbd9ffb3e2344e1cb161206ebec1b300,
title = "Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine-induced weight gain",
abstract = "Background Olanzapine is an atypical antipsychotic known to cause considerable weight gain. The cannabinoid type 1 receptor has been reported to be involved in energy balance control, appetite stimulation, and increases in body weight. Methods In the present study, we investigated three polymorphisms (rs1049353, rs806368, and rs4707436) in the cannabinoid type 1 receptor gene (CNR1) and weight gain in Korean patients with schizophrenia receiving olanzapine treatment. Weight and height were measured prior to starting olanzapine and again after long-term treatment in 78 patients with schizophrenia. CNR1 polymorphisms were genotyped using PCR-RFLP methods. Results The three CNR1 polymorphisms were not associated with body weight changes from baseline to the endpoint after olanzapine treatment (p > 0.05). There were also no significant differences in genotype, allele, or haplotype frequencies between the high weight gain (at least 7{\%}) and low weight gain (less than 7{\%}) groups. Conclusion Within the limitations imposed by the smallness of the clinical sample, our findings suggest that CNR1 polymorphisms are not associated with olanzapine-induced weight gain.",
keywords = "cannabinoid receptor, olanzapine, polymorphism, schizophrenia, weight gain",
author = "Park, {Young Min} and Choi, {Jung Eun} and Kang, {Seung Gul} and Seung-Hoi Koo and Leen Kim and Dongho Geum and Heon-Jeong Lee",
year = "2011",
month = "6",
day = "1",
doi = "10.1002/hup.1210",
language = "English",
volume = "26",
pages = "332--337",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "4-5",

}

TY - JOUR

T1 - Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine-induced weight gain

AU - Park, Young Min

AU - Choi, Jung Eun

AU - Kang, Seung Gul

AU - Koo, Seung-Hoi

AU - Kim, Leen

AU - Geum, Dongho

AU - Lee, Heon-Jeong

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Background Olanzapine is an atypical antipsychotic known to cause considerable weight gain. The cannabinoid type 1 receptor has been reported to be involved in energy balance control, appetite stimulation, and increases in body weight. Methods In the present study, we investigated three polymorphisms (rs1049353, rs806368, and rs4707436) in the cannabinoid type 1 receptor gene (CNR1) and weight gain in Korean patients with schizophrenia receiving olanzapine treatment. Weight and height were measured prior to starting olanzapine and again after long-term treatment in 78 patients with schizophrenia. CNR1 polymorphisms were genotyped using PCR-RFLP methods. Results The three CNR1 polymorphisms were not associated with body weight changes from baseline to the endpoint after olanzapine treatment (p > 0.05). There were also no significant differences in genotype, allele, or haplotype frequencies between the high weight gain (at least 7%) and low weight gain (less than 7%) groups. Conclusion Within the limitations imposed by the smallness of the clinical sample, our findings suggest that CNR1 polymorphisms are not associated with olanzapine-induced weight gain.

AB - Background Olanzapine is an atypical antipsychotic known to cause considerable weight gain. The cannabinoid type 1 receptor has been reported to be involved in energy balance control, appetite stimulation, and increases in body weight. Methods In the present study, we investigated three polymorphisms (rs1049353, rs806368, and rs4707436) in the cannabinoid type 1 receptor gene (CNR1) and weight gain in Korean patients with schizophrenia receiving olanzapine treatment. Weight and height were measured prior to starting olanzapine and again after long-term treatment in 78 patients with schizophrenia. CNR1 polymorphisms were genotyped using PCR-RFLP methods. Results The three CNR1 polymorphisms were not associated with body weight changes from baseline to the endpoint after olanzapine treatment (p > 0.05). There were also no significant differences in genotype, allele, or haplotype frequencies between the high weight gain (at least 7%) and low weight gain (less than 7%) groups. Conclusion Within the limitations imposed by the smallness of the clinical sample, our findings suggest that CNR1 polymorphisms are not associated with olanzapine-induced weight gain.

KW - cannabinoid receptor

KW - olanzapine

KW - polymorphism

KW - schizophrenia

KW - weight gain

UR - http://www.scopus.com/inward/record.url?scp=79960835205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960835205&partnerID=8YFLogxK

U2 - 10.1002/hup.1210

DO - 10.1002/hup.1210

M3 - Article

C2 - 21695734

AN - SCOPUS:79960835205

VL - 26

SP - 332

EP - 337

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 4-5

ER -